Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells

Blood

Volumn 102, Issue 6, 2003, Pages 1966-1977

  Salcedo, Rosalba ^a   Zhang, Xia ^b   Young, Howard A ^b   Michael, Nelson ^b   Wasserman, Ken ^b   Ma, Wei Hong ^b   Martins Green, Manuela ^b   Murphy, William J ^b   Oppenheim, Joost J ^b  

^a Bldg 567   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENYLATE CYCLASE; BASIC FIBROBLAST GROWTH FACTOR; CHEMOKINE RECEPTOR CXCR4; FORSKOLIN; ISOBUTYLMETHYLXANTHINE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PIROXICAM; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SCID MOUSE; VASCULAR ENDOTHELIUM; VASCULARIZATION;

EID: 0141679091     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-11-3400     Document Type: Article

References (76)

1. Strieter RM, Polverini PJ, Kunkel SL, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem. 1995;270:27348-27357.
2. Schneider GP, Salcedo R, Welniak LA, Howard OM, Murphy WJ. The diverse role of chemokines in tumor progression: prospects for intervention [review]. Int J Mol Med. 2001;8:235-244.
3. Bernardini G, Spinetti G, Ribatti D, et al. 1-309 binds to and activates endothelial cell functions and acts as an angiogenic molecule in vivo. Blood. 2000;96:4039-4045.
4. Oberlin E, Amara A, Bachelerie F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature. 1996;382:833-835.
5. + progenitors to peripheral blood. J Exp Med. 1997;185:111-120.
6. Gupta SK, Lysko PG, Pillarisetti K, Ohlstein E, Stadel JM. Chemokine receptors in human endothelial cells: functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines. J Biol Chem. 1998;273:4282-4287.
7. Volin MV, Joseph L, Shockley MS, Davies PF. Chemokine receptor CXCR4 expression in endothelium. Biochem Biophys Res Commun. 1998;242:46-53.
8. Feil C, Augustin HG. Endothelial cells differentially express functional CXC-chemokine receptor-4 (CXCR-4/fusin) under the control of autocrine activity and exogenous cytokines. Biochem Biophys Res Commun. 1998;247:38-45.
9. Nagasawa T, Tachibana K, Kishimoto T. A novel CXC chemokine PBSF/SDF-1 and its receptor CXCR4: their functions in development, hematopoiesis and HIV infection. Semin Immunol. 1998;10:179-185.
10. Tachibana K, Hirota S, Iizasa H, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature. 1998;393:591-594.
11. Salcedo R, Wasserman K, Young HA, et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1 alpha. Am J Pathol. 1999;154:1125-1135.
12. Wheeler-Jones C, Abu-Ghazaleh R, Cospedal R, Houliston RA, Martin J, Zachary I. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett. 1997;420:28-32.
13. Kage K, Fujita N, Oh-hara T, Ogata E, Fujita T, Tsuruo T. Basic fibroblast growth factor induces cyclooxygenase-2 expression in endothelial cells derived from bone. Biochem Biophys Res Commun. 1999;254:259-263.
14. He H, Venema VJ, Gu X, Venema RC, Marrero MB, Caldwell RB. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem. 1999;274:25130-25135.
15. 2+. Biochem J. 2001;353:503-512.
16. Krishnamurthy P, Bird IM, Sheppard C, Magness RR. Effects of angiogenic growth factors on endothelium-derived prostacyclin production by ovine uterine and placental arteries. Prostaglandins Other Lipid Mediat. 1999;57:1-12.
17. Hernandez GL, Volpert OV, Iniguez MA, et al. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med. 2001;193:607-620.
18. Gerritsen ME, Cheli CD. Arachidonic acid and prostaglandin endoperoxide metabolism in isolated rabbit and coronary microvessels and isolated and cultivated coronary microvessel endothelial cells. J Clin Invest. 1983;72:1658-1671.
19. Gerritsen ME, Niedbala MJ, Szczepanski A, Carley WW. Cytokine activation of human macro-and microvessel-derived endothelial cells. Blood Cells. 1993;19:325-339; discussion 340-342.
20. Gerritsen ME, Rimarachin J, Perry CA, Weinstein BI. Arachidonic acid metabolism by cultured bovine corneal endothelial cells. Invest Ophthalmol Vis Sci. 1989;30:698-705.
21. Carley WW, Niedbala MJ, Gerritsen ME. Isolation, cultivation, and partial characterization of microvascular endothelium derived from human lung. Am J Respir Cell Mol Biol. 1992;7:620-630.
22. Dempke W, Rie C, Grothey A, Schmoll HJ. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol. 2001;127:411-417.
23. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063-1073.
24. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705-716.
25. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000;60:1306-1311.
26. Leahy KM, Koki AT, Masferrer JL. Role of cyclooxygenases in angiogenesis. Curr Med Chem. 2000;7:1163-1170.
27. Peterson HI. Effects of prostaglandin synthesis inhibitors on tumor growth and vascularization: experimental studies in the rat. Invasion Metastasis. 1983;3:151-159.
28. BenEzra D. Neovasculogenic ability of prostaglandins, growth factors, and synthetic chemoattractants. Am J Ophthalmol. 1978;86:455-461.
29. 2 and angiogenesis. Proc Soc Exp Biol Med. 1983;172:214-218.
30. Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med. 1999;5:1418-1423.
31. Kanayasu T, Nakao-Hayashi J, Asuwa N, et al. Leukotriene C4 stimulates angiogenesis in bovine carotid artery endothelial cells in vitro. Biochem Biophys Res Commun. 1989;159:572-578.
32. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res. 2001;49:568-581.
33. Murohara T, Horowitz JR, Silver M, et al. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation. 1998;97:99-107.
34. Ashton AW, Dawes J, Chesterman CN. Acidic and basic fibroblast growth factors have comparable effects on the haemostatic function of vascular endothelium. Growth Factors. 1995;12:111-120.
35. Moatter T, Gerritsen ME. Acidic fibroblast factor induction of cyclooxygenase II in rabbit cardiac muscle microvessel endothelial cells: mediation by protein kinase C. Microcirculation. 1994;1:79-88.
36. Moatter T, Gerritsen ME. Fibroblast growth factor upregulates PGG/H synthase in rabbit microvascular endothelial cells by a glucocorticoid independent mechanism. J Cell Physiol. 1992;151:571-578.
37. Hube F, Lee YM, Rohrig K, Hauner H. The phosphodiesterase inhibitor IBMX suppresses TNF-alpha expression in human adipocyte precursor cells: a possible explanation for its adipogenic effect. Horm Metab Res. 1999;31:359-362.
38. Lomo J, Blomhoff HK, Beiske K, Stokke T, Smeland EB. TGF-beta 1 and cyclic AMP promote apoptosis in resting human B lymphocytes. J Immunol. 1995;154:1634-1643.
39. Gjertsen BT, Mellgren G, Otten A, et al. Novel (Rp)-cAMPS analogs as tools for inhibition of cAMP-kinase in cell culture: basal cAMP-kinase activity modulates interleukin-1 beta action. J Biol Chem. 1995;270:20599-20607.
40. Mohammed SI, Bennett PF, Craig BA, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res. 2002;62:356-358.
41. + endothelial cells. J Immunol. 2001;166:7571-7578.
42. Wegner SA, Ehrenberg PK, Chang G, Dayhoff DE, Sleeker AL, Michael NL. Genomic organization and functional characterization of the chemokine receptor CXCR4, a major entry co-receptor for human immunodeficiency virus type 1. J Biol Chem. 1998;273:4754-4760.
43. 2: effects on corneal endothelial cell migration and monolayer spreading during wound repair in vitro. Curr Eye Res. 1995;14:601-609.
44. Salcedo R, Resau JH, Halverson D, et al. Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB J. 2000;14:2055-2064.
45. Salcedo R, Ponce ML, Young HA, et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood. 2000;96:34-40.
46. Regan JW, Bailey TJ, Pepperl DJ, et al. Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. Mol Pharmacol. 1994;46:213-220.
47. Bastien L, Sawyer N, Grygorczyk R, Metters KM, Adam M. Cloning, functional expression, and characterization of the human prostaglandin E2 receptor EP2 subtype. J Biol Chem. 1994;269:11873-11877.
48. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol. 2001;41:661-690.
49. Bryant CE, Appleton I, Mitchell JA. Vascular endothelial growth factor upregulates constitutive cyclooxygenase 1 in primary bovine and human endothelial cells. Life Sci. 1998;62:2195-2201.
50. Chulada PC, Thompson MB, Mahler JF, et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res. 2000;60:4705-4708.
51. Smith WL, Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest. 2001;107:1491-1495.
52. Langenbach R, Morham SG, Tiano HF, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell. 1995;83:483-492.
53. Morham SG, Langenbach R, Loftin CD, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell. 1995;83:473-482.
54. Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature. 1995;378:406-409.
55. 2 biosynthesis in cyclooxygenase 1 or 2 null cells. J Exp Med. 1998;187:517-523.
56. Fang C, Alexander JW, MacMillan BG, Austin LS. Failure of topical prostaglandin inhibitors to improve wound healing following deep partial-thickness burns. J Trauma. 1983;23:300-304.
57. Laulederkind SJ, Thompson-Jaeger S, Goorha S, et al. Both constitutive and inducible prostaglandin H synthase affect dermal wound healing in mice. Lab Invest. 2002;82:919-927.
58. Davis CM, Danehower SC, Laurenza A, Molony JL. Identification of a role of the vitronectin receptor and protein kinase C in the induction of endothelial cell vascular formation. J Cell Biochem. 1993;51:206-218.
59. Dallabrida SM, De Sousa MA, Farrell DH. Expression of antisense to integrin subunit beta 3 inhibits microvascular endothelial cell capillary tube formation in fibrin. J Biol Chem. 2000;275:32281-32288.
60. Bach TL, Barsigian C, Chalupowicz DG, et al. VE-cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels. Exp Cell Res. 1998;238:324-334.
61. Bell SE, Mavila A, Salazar R, et al. Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. J Cell Sci. 2001;114:2755-2773.
62. Yang S, Graham J, Kahn JW, Schwartz EA, Gerritsen ME. Functional roles for PECAM-1 (CD31) and VE-cadherin (CD144) in tube assembly and lumen formation in three-dimensional collagen gels. Am J Pathol. 1999;155:887-895.
63. Rohlff C, Glazer RI. Regulation of the MDR1 promoter by cyclic AMP-dependent protein kinase and transcription factor Sp1. Int J Oncol. 1998;12:383-386.
64. Wallace JL, Bak A, McKnight W, Asfaha S, Sharkey KA, MacNaughton WK. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology. 1998;115:101-109.
65. Mizuno H, Sakamoto C, Matsuda K, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology. 1997;112:387-397.
66. Shigeta J, Takahashi S, Okabe S. Role of cyclooxygenase-2 in the healing of gastric ulcers in rats. J Pharmacol Exp Ther. 1998;286:1383-1390.
67. Konturek PC, Brzozowski T, Konturek SJ, et al. Activation of genes for growth factors and cyclooxygenases in rat gastric mucosa during recovery from stress damage. Eur J Pharmacol. 1998;342:55-65.
68. Schmassmann A, Peskar BM, Stettler C, et al. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol. 1998;123:795-804.
69. Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology. 2000;119:706-714.
70. Hawkey CJ, Rampton DS. Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease, or treatment? Gastroenterology. 1985;89:1162-1188.
71. Rampton DS, Hawkey CJ. Prostaglandins and ulcerative colitis. Gut. 1984;25:1399-1413.
72. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum. 1998;41:1591-1602.
73. Bodolay E, Koch AE, Kim J, Szegedi G, Szekanecz Z. Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J Cell Mol Med. 2002;6:357-376.
74. Dredge K, Dalgleish AG, Marriott JB. Recent developments in antiangiogenic therapy. Expert Opin Biol Ther. 2002;2:953-966.
75. Pablos JL, Santiago B, Galindo M, et al. Synoviocyte-derived CXCL12 is displayed on endothelium and induces angiogenesis in rheumatoid arthritis. J Immunol. 2003;170:2147-2152.
76. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50-56.